|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Invitrogen Corporation, (Nasdaq: IVGN), a provider of technologies for disease, drug discovery and commercial bioproduction. |
|---|---|
| Transferring Party | BioSource International (BIOI), a provider of products and services supporting biomedical research by producing animal- or human-based nucleic acids and proteins. |
| Sector | Biopharmaceuticals |
| Date | July 26, 2005 |
| Analysis Broadens Invitrogen's collection of protein and primary antibody products which were added through the prior acquisitions of Zymed Labs and Caltag Labs. Expands Invitrogen's offerings in kinase and cytokine assay technologies for research applications and provides entre into new markets: immunology, oncology and neurodegenerative disease. The Deal value about $130 million. BioSource's revenues were $47.3 million and EBITDA $4.6 million | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |